Comparative Pharmacology
Head-to-head clinical analysis: DARVON versus ROXILOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVON versus ROXILOX.
DARVON vs ROXILOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a mu-opioid receptor agonist that inhibits ascending pain pathways by binding to opioid receptors in the CNS, altering pain perception. It also has weak local anesthetic effects.
Roxilox is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Propoxyphene hydrochloride (Darvon) for moderate to severe pain: 65 mg orally every 4 hours as needed; maximum 390 mg/day.
10 mg orally once daily, with or without food.
None Documented
None Documented
6-12 hours (parent drug); norpropoxyphene half-life 30-36 hours, accumulates with repeated dosing, increasing risk of toxicity.
Terminal elimination half-life 4.5 hours; prolonged to 18-24 hours in severe renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism to norpropoxyphene, then renal excretion of metabolites; <20% excreted unchanged in urine; minor biliary/fecal elimination.
Renal (70-80% unchanged), biliary/fecal (15-20%), remainder metabolized
Category C
Category C
Opioid Analgesic
Opioid Analgesic